DexCom heads into Q4 earnings with easing G7 issues, improving supply chains and rebounding U.S. new customer starts lifting revenue outlook.
Dexcom plans a nationwide AI upgrade to Stelo, adding a million-plus food database and smarter insights to improve glucose understanding and wellness goals.
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.
DXCM looks poised for growth as CGM demand expands, G7 and One+ adoption accelerates, and strong Q4 results support a hold stance.
DexCom, Inc. (DXCM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.